SERPINE1
|
Diabetes Mellitus
|
0.300 |
AlteredExpression |
BEFREE |
Elevated PAI-1 levels may be associated with an increased risk for diabetes as a marker for underlying endothelial dysfunction rather than by a direct effect of genetically mediated elevated levels.
|
16855181 |
2006 |
SERPINE1
|
Diabetes Mellitus
|
0.300 |
AlteredExpression |
BEFREE |
Elevated levels of plasminogen activator inhibitor-1 (PAI-1) are associated with myocardial infarction and stroke, especially in patients with diabetes.
|
15956119 |
2005 |
SERPINE1
|
Diabetes Mellitus
|
0.300 |
AlteredExpression |
BEFREE |
Its effects on ROS production, AP-1 activity, plasminogen activator inhibitor 1 (PAI-1) gene expression, and cellular proliferation and migration were measured in response to high glucose and angiotensin II (Ang II) concentrations, two major factors in the pathogenesis of atherosclerosis in patients with diabetes and hypertension.
|
15827742 |
2005 |
SERPINE1
|
Diabetes Mellitus
|
0.300 |
AlteredExpression |
BEFREE |
In 45/112 patients without the established risk factors for RVO (hyper-tension, hypercholesterolemia and diabetes) or characteristics known to be associated to increased PAI-1 activity (overweight, hypertriglyceridemia, and smoking habit) the contemporary presence of ACE DD and PAI-1 4G4G genotype was significantly associated with a risk for RVO (OR = 8.26, 95% CI 1.18-57.92; p = 0.034).
|
15213845 |
2004 |
SERPINE1
|
Diabetes Mellitus
|
0.300 |
GeneticVariation |
BEFREE |
Interaction between genotype and diabetes status was estimated for nine CVD risk factors [body fat mass (FAT), body mass index (BMI), high-density lipoprotein cholesterol (HDL-C), log-transformed fibrinogen, log-transformed triglycerides, log-transformed urinary albumin : creatinine ratio (LACR), plasminogen activator inhibitor 1 (PAI-1), systolic blood pressure (SBP), and waist-to-hip ratio (WHR)], using a maximum likelihood variance decomposition technique.
|
12673782 |
2003 |
SERPINE1
|
Diabetes Mellitus
|
0.300 |
AlteredExpression |
BEFREE |
The results of the present study suggest that LDL and VLDL from patients with DM reduce the generation of tPA and increase PAI-1 production through the activation of the PAI-1 promoter in vascular EC.
|
11788661 |
2002 |
SERPINE1
|
Diabetes Mellitus
|
0.300 |
Biomarker |
BEFREE |
Concentrations in blood of plasminogen activator inhibitor type 1 (PAI-1) and circulating free (non-esterified) fatty acids (FFA) are increased in diabetes and may accelerate atherosclerosis.
|
12669679 |
2002 |
SERPINE1
|
Diabetes Mellitus
|
0.300 |
Biomarker |
BEFREE |
To evaluate whether hyperglycaemia in two lean patients with primary severe insulin resistance due to insulin receptor (IR) mutations and diabetes mellitus could be reduced by supplement of rosiglitazone for 180 days and secondary, to evaluate the effects on plasma NEFA, TG, Apo B, PAI-1 and serum insulin.
|
11887975 |
2001 |
SERPINE1
|
Diabetes Mellitus
|
0.300 |
AlteredExpression |
BEFREE |
A multiple linear regression model with independent variables (age, body-mass index, total cholesterol level, triglyceride level, ACE I/D genotype, and PAI-1 genotype due to a single guanine I/D polymorphism in the PAI-1 gene) demonstrated that the triglyceride level (P = 0.0059) and ACE I/D genotype (P = 0.0372) were independent predictors of plasma PAI-1 antigen levels in a subset of the subjects without diabetes mellitus that were not taking lipid-lowering drugs.
|
10759003 |
2000 |
SERPINE1
|
Diabetes Mellitus
|
0.300 |
GeneticVariation |
BEFREE |
The PAI-1 and ACE (D/I) gene polymorphisms were examined in a cohort of Chinese type 2 diabetic patients who had diabetes for an average of 14 years.
|
10652041 |
2000 |
SERPINE1
|
Diabetes Mellitus
|
0.300 |
Biomarker |
BEFREE |
Polymorphisms of angiotensin converting enzyme and plasminogen activator inhibitor-1 genes in diabetes and macroangiopathy1.
|
9844142 |
1998 |
SERPINE1
|
Diabetes Mellitus
|
0.300 |
AlteredExpression |
BEFREE |
In a logistic regression analysis controlled for age, sex, BMI, and duration of diabetes, any retinopathy was significantly associated with fasting plasma glucose concentrations (P < 0.05), 2-h postload glucose (P = 0.02), and HbA1c (P = 0.008), but not with PAI-1 activity (P = 0.48).
|
9250459 |
1997 |
SERPINE1
|
Diabetes Mellitus
|
0.300 |
Biomarker |
BEFREE |
Elevated plasminogen activator inhibitor-1 may contribute to vascular disease in diabetes mellitus.
|
8960834 |
1996 |
SERPINE1
|
Diabetes Mellitus
|
0.300 |
AlteredExpression |
BEFREE |
The results indicate that there is no or minimal influence of the PAI-1 gene on either PAI-1 levels or the development of diabetic retinopathy in patients with diabetes mellitus.
|
7974340 |
1994 |